InterCure Ltd. INCR
- Market cap
- $62.3M
- P/E
- 9.8×
Follow INCR
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 4.75 | 1.50 | 5.75 | 16.35 | 4.95 | 5.85 | 3.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 21.75 | 11.00 | 49.95 | 41.00 | 20.00 | 18.60 | 8.95 |
High Price
|
|||
| — | — | — | — | — | 350 | 370 | 270 | 320 | 285 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 3 | 20 | 70 | 120 | 97 | 66 | 78 |
Revenue
|
|||
| — | 0.00% | 0.00% | 13.07% | 45.58% | 40.28% | 38.60% | 29.54% | 12.32% | 12.27% |
Gross Margin
|
|||
| 0 | (2) | (3) | (2) | (12) | 6 | 13 | (17) | (24) | (13) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | (69.75%) | (58.90%) | 8.28% | 10.91% | (17.22%) | (35.60%) | (16.32%) |
EBT Margin
|
|||
| 0 | 0 | (3) | (2) | (12) | 2 | 13 | (17) | (20) | (11) |
Net Income
|
|||
| — | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 4 | 5 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.11 | 0.80 | 9.10 | 13.20 | 10.60 | 7.23 | 7.30 |
Revenue/Sh
|
|||
| 0.01 | (0.09) | (0.19) | (0.07) | (0.46) | 0.20 | 1.50 | (1.85) | (2.00) | (0.95) |
Earnings/Sh
|
|||
| (0.02) | (0.02) | (0.02) | (0.14) | 0.10 | 1.01 | 1.68 | (1.60) | (1.97) | 0.46 |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.56) | (0.65) | (0.08) | (0.14) | (0.10) |
Capex/Sh
|
|||
| (0.02) | (0.02) | (0.02) | (0.14) | 0.10 | 0.44 | 1.04 | (1.68) | (2.11) | 0.36 |
Free CF/Sh
|
|||
| 0.50 | 0.35 | 0.29 | 3.18 | 3.37 | 18.46 | 17.13 | 13.62 | 11.71 | 10.71 |
Book Value/Sh
|
|||
| 13 | 17 | 18 | 23 | 25 | 8 | 9 | 9 | 9 | 11 |
Shares
|
|||
| — | — | — | 50.92 | 50.92 | 205.98 | 11.09 | 12.31 | 15.01 | 8.59 |
PE Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 21.03 | 1.34 | 2.47 | 3.01 | 1.73 |
PS Ratio
|
|||
| — | — | — | 2.73 | 2.05 | 10.12 | 1.04 | 2.06 | 2.92 | 1.72 |
PB Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 20.52 | 1.04 | 2.45 | 3.12 | 1.87 |
EV/Sales
|
|||
| — | — | — | 0.00 | 0.00 | 140.88 | 13.24 | (70.51) | (89.93) | (279.22) |
EV/FCF
|
|||
| 0 | 0 | 0 | (3) | 2 | 8 | 15 | (15) | (18) | 5 |
Op' Cash Flow
|
|||
| 0 | — | 0 | (8) | (6) | (4) | (6) | (1) | (1) | (1) |
Capex
|
|||
| 0 | 0 | 0 | (3) | 2 | 3 | 9 | (15) | (19) | 4 |
FCF
|
|||
| 0 | 0 | (3) | 6 | 15 | 44 | 58 | 52 | 45 | 30 |
Working Cap'
|
|||
| 1 | 1 | 3 | 5 | 2 | 11 | 37 | 28 | 37 | 26 |
Total Debt
|
|||
| 0 | 0 | 2 | (3) | (10) | (57) | (37) | (2) | 15 | 12 |
Net Debt
|
|||
| 6 | 6 | 5 | 74 | 86 | 142 | 155 | 124 | 107 | 115 |
Sh' Equity
|
|||
| 0.98% | (43.41%) | (71.26%) | (3.74%) | (12.66%) | 0.92% | 5.36% | (6.74%) | (8.73%) | (5.10%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.37% | 7.94% | (5.79%) | (9.23%) | (3.90%) |
ROIC
|
|||
| 1.13% | (25.66%) | (60.96%) | (4.30%) | (14.54%) | 1.28% | 8.98% | (12.04%) | (15.82%) | (9.32%) |
ROE
|
|||
InterCure Ltd. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TLPH Talphera, Inc. | $60.7M | 0.0× | Compare |
| SCYX SCYNEXIS, Inc. | $45.0M | 0.0× | Compare |
| IXHL Incannex Healthcare Inc. | $40.7M | 0.0× | Compare |
| CLVR Clever Leaves Holdings Inc. | $96.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ZYBT Zhengye Biotechnology Holding Limited | $40.1M | — | Compare |
| CTOR Citius Oncology, Inc. | $97.6M | 0.0× | Compare |
| BGM BGM Group Ltd. | $104.6M | 4.0× | Compare |
| RMTI Rockwell Medical, Inc. | $34.5M | 0.0× | Compare |
InterCure Ltd. (INCR) key facts
- InterCure Ltd. (INCR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was ILS 78.5 million, up 18.4% from fiscal 2024.
- As of September 25, 2026, INCR traded at $5.21, a market capitalization of $62.3 million.
- Return on equity was −9.32% and debt-to-equity 0.27.
InterCure Ltd. (INCR) Latest News
27 Aug
InterCure finalized a $77M settlement with uncertainty over the amount of new cash to be received. A $77M settlement creates notable financial uncertainty that may affect InterCure cash flow and operations.
24 Aug
InterCure Ltd. finalized a NIS 230 million settlement, equivalent to about US$77 million, covering war-related indirect damages. The one-time US$77 million cash receipt strengthens InterCure's balance sheet without altering core operations or long-term strategy.
22 Jun
InterCure Ltd. raised NIS 22 million via private placement led by pharma-focused hedge funds. Capital raise strengthens balance sheet and may aid operations with moderate financial effects.
15 Jun
InterCure Ltd. launches a strategic review of U.S. medical cannabis opportunities after federal rescheduling and completes initial closing of Botanico acquisition. Historic rescheduling opens U.S. market review while Botanico acquisition advances InterCure expansion and trajectory.
30 Apr
InterCure Ltd. (INCR) announced 2025 results with NIS 270 million in revenue and positive operating cash flow. Strong revenue of NIS 270 million and positive operating cash flow demonstrate significant financial improvement and enhanced market position.
3 Mar
InterCure Ltd. (INCR) received a Nasdaq notification for failing to satisfy the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to comply risks delisting proceedings, though InterCure can appeal or potentially qualify for a reverse stock split. Nasdaq minimum bid deficiency notice introduces delisting risk, significantly pressuring stock price and investor sentiment.
19 Feb
InterCure Ltd. (INCR) announced preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA, and cash reserves of NIS 43 million. Strong preliminary 2025 revenue guidance and positive EBITDA outlook signal significant positive impact on financial trajectory and investor sentiment.
InterCure Ltd. (INCR) announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA, and cash of NIS 43 million. Strong preliminary 2025 financial guidance with robust revenue, positive EBITDA, and solid cash position significantly boosts investor sentiment and future performance outlook.
3 Nov
InterCure Ltd. has entered into strategic investment and collaboration agreements with Cannasoul to enhance cannabis science and pharmaceutical innovation. This partnership aims to leverage both companies' expertise to advance research and development in the cannabis sector, potentially leading to new therapeutic applications and improved product offerings. The collaboration is expected to significantly impact product innovation and market positioning in the cannabis industry.
8 Oct
InterCure Ltd. reported NIS 130 million in revenue for the first half of 2025, achieving positive operating cash flow. The company continues to demonstrate growth and financial stability in its operations, reflecting a strong market position in the cannabis sector. Positive operating cash flow and significant revenue indicate a strong performance that could influence investor sentiment and future growth.
InterCure Ltd. reported NIS 130 million in revenue for the first half of 2025, demonstrating positive operating cash flow. The company's financial performance reflects growth and operational efficiency, positioning it favorably in the market. Positive operating cash flow and significant revenue indicate a strong financial position that could influence future performance.
29 Sep
InterCure Ltd. (INCR) is highlighted among Middle Eastern penny stocks with market capitalizations exceeding US$1 million. The company is noted for its operations in the cannabis sector, which has been gaining traction in the region. Investors are increasingly looking at such stocks for potential growth opportunities as the market evolves. The cannabis sector's growth in the Middle East may moderately influence InterCure's market positioning and financial performance.
19 Sep
InterCure Ltd. has entered the premium U.S. cannabis market through a strategic partnership with ISHI, aiming to leverage ISHI's established distribution channels and brand recognition. This deal is expected to enhance InterCure's market presence and drive growth in the burgeoning cannabis sector, aligning with the company's expansion strategy in North America. The partnership with ISHI is a significant strategic move that could enhance market positioning and investor sentiment.
InterCure Ltd. (INCR) has announced plans to acquire the cannabis brand Botanico in a two-phase deal. The acquisition aims to enhance InterCure's product offerings and market presence. The first phase involves an initial payment, while the second phase is contingent on performance milestones. This strategic move is expected to strengthen InterCure's position in the competitive cannabis market. The acquisition of Botanico is a significant strategic move that could enhance InterCure's market position and product portfolio.
InterCure Ltd. has announced the strategic acquisition of ISHI, a move that provides access to premium U.S. cannabis technology and brands. This acquisition is expected to enhance InterCure's product offerings and strengthen its position in the cannabis market, aligning with the company's growth strategy and expanding its operational capabilities. The acquisition of ISHI is a significant strategic move that could enhance product offerings and market positioning.
8 Aug
InterCure Ltd. (INCR) is highlighted as a promising investment opportunity among Middle Eastern penny stocks in August 2025. The article emphasizes the company's potential for growth in the cannabis sector, driven by increasing demand and favorable regulatory changes in the region. Analysts suggest that InterCure's strategic initiatives and market positioning could lead to significant returns for investors looking for hidden opportunities in this emerging market. InterCure's strategic initiatives and favorable market conditions are likely to significantly impact its future performance.
1 May
InterCure Ltd. reported FY2024 revenue of NIS 239 million and Adjusted EBITDA of NIS 24 million, impacted by damages from the October 7 terrorist attack and ongoing conflict in Gaza. The company received NIS 62 million in compensation from Israeli authorities and expects further payments. A strong start to Q1 2025 is anticipated with over 25% sequential growth, supported by NIS 66 million in funding for facility recovery. InterCure is expanding its partnership with Cookies™ into Germany and plans to launch new products while restoring its southern facility. The company ended 2024 with NIS 80 million in cash and aims for continued double-digit growth throughout 2025. The expansion into new markets and recovery efforts following significant damages are likely to significantly impact future performance.
InterCure announced FY2023 results with revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million. The significant impact of the war and terrorist attack on revenues and the company's expansion plans could alter its trajectory.
12 Feb
InterCure Ltd. has appointed Alexander Rabinovich as the new Chairman, succeeding Ehud Barak. This leadership change is expected to influence the company's strategic direction and governance. Leadership changes can moderately influence a company's strategic direction and operational effectiveness.
20 Dec
InterCure Ltd. secures funding of NIS 66M, potentially increasing to NIS 107M, to support recovery and expansion of Nir Oz Facility post-war. Significant impact likely on future and performance due to major funding secured for recovery and expansion efforts.
1 Sep
InterCure Ltd. reported a break-even first half of 2024 despite disruptions from the Israel-Hamas conflict. InterCure's financial performance and strategic actions are expected to significantly impact its future trajectory.
29 Aug
InterCure Ltd. announced first half of 2024 results with revenue of NIS 126 million and adjusted EBITDA of NIS 21 million. The company's profitability was affected by damages from a terrorist attack and war in Gaza, but it expects double-digit growth in the second half of 2024. The article highlights significant financial results, strategic partnerships, and expansion plans that are expected to have a major impact on InterCure Ltd.'s future performance.
28 Aug
InterCure expands partnership with Cookies to launch Cookies Corners licensed pharmacies in Germany, offering branded products through online platforms. Expansion into Germany with globally recognized cannabis brand expected to significantly impact InterCure's future market performance.
22 May
InterCure to participate in Canaccord Genuity's 8th Annual Global Cannabis Conference. Participation in a global cannabis conference may moderately influence InterCure's competitive positioning and market performance.
1 Apr
InterCure Ltd. announces preliminary estimated 2023 revenue of NIS 351 million and EBITDA of over NIS 50 million, despite being affected by damages from a terrorist attack and war in Gaza. The significant impact of the damages and war situation on the company's operations and financial performance is expected to alter its trajectory and investor sentiment.
22 Mar
InterCure congratulates Germany on cannabis reform, plans to launch products in Germany soon. The passing of the Cannabis Act in Germany and InterCure's plans to launch products in the country are expected to have a significant impact on the company's future and market performance.
13 Feb
InterCure provides update on Nir Oz facility in Israel following war declaration. The war situation in Israel and impact on the company's facility is expected to have a significant influence on its future operations and market performance.
31 Jan
InterCure Ltd. signs definitive agreement to acquire Leon Cannabis Pharmacy Chain. Acquisition of pharmacy chain expected to have significant impact on future market performance.
31 Oct
InterCure wins arbitration proceeding regarding Cannolam, now holds 100% shares in the company. Arbitration decision significantly impacts InterCure's ownership and operations.
17 Oct
InterCure Ltd. addresses security situation in Israel following Hamas attacks, commits to supporting affected communities. The article highlights potential significant impact on InterCure's operations and financial results due to the war and damages suffered at its main facility.